Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21542429 | 0.77 | CHRM1 (0.35) | — | |
| SCHEMBL31116092 | 0.76 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL19614682 | 0.74 | GRM1 (0.34) | ALDH1A1 | |
| SCHEMBL10210793 | 0.74 | ALDH1A1 (0.35) | ALDH1A1 | |
| SCHEMBL21542371 | 0.74 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL16700084 | 0.74 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL23327561 | 0.73 | CYP4F2 (0.32) | — | |
| SCHEMBL478303 | 0.71 | GRM1 (0.40) | — | |
| SCHEMBL4036460 | 0.69 | ALDH1A1 (0.33) | ALDH1A1 | |
| SCHEMBL10160156 | 0.69 | ALDH1A1 (0.33) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240132523-A1 | SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR | INCYTE CORPORATION | 2024-04-25 | — | — | US | claimed |
| CN-114829366-A | Salts and crystalline forms of PD-1/PD-L1 inhibitors | 因赛特公司 | 2022-07-29 | — | — | CN | claimed |
| WO-2021096849-A1 | SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR | INCYTE CORPORATION (US) | 2021-05-20 | — | — | WO | claimed |
| US-20210139511-A1 | SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR | INCYTE CORPORATION | 2021-05-13 | — | — | US | claimed |
| US-20240132523-A1 | SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR | INCYTE CORPORATION | 2024-04-25 | — | — | US | disclosed |
| WO-2024018403-A1 | SUBSTITUTED IMIDAZOAMIDE COMPOUNDS, AND METHODS USING SAME | ARBUTUS BIOPHARMA CORPORATION (CA) | 2024-01-25 | — | — | WO | disclosed |
| US-11866451-B2 | Salts and crystalline forms of a PD-1/PD-L1 inhibitor | INCYTE CORPORATION (US) | 2024-01-09 | — | — | US | disclosed |
| WO-2022161421-A1 | BIPHENYL COMPOUND AS IMMUNOMODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 深圳微芯生物科技股份有限公司 | 2022-08-04 | — | — | WO | disclosed |
| CN-114829366-A | Salts and crystalline forms of PD-1/PD-L1 inhibitors | 因赛特公司 | 2022-07-29 | — | — | CN | disclosed |
| WO-2022089511-A1 | BIPHENYL COMPOUND AS IMMUNOMODULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF | 深圳微芯生物科技股份有限公司 | 2022-05-05 | — | — | WO | disclosed |
| WO-2021139647-A1 | BIPHENYL FLUORINE DOUBLE BOND DERIVATIVE, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL APPLICATION THEREOF | 上海和誉生物医药科技有限公司 | 2021-07-15 | — | — | WO | disclosed |
| WO-2021096849-A1 | SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR | INCYTE CORPORATION (US) | 2021-05-20 | — | — | WO | disclosed |
| WO-2021096849-A1 | SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR | INCYTE CORPORATION (US) | 2021-05-20 | — | — | WO | disclosed |
| US-20210139511-A1 | SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR | INCYTE CORPORATION | 2021-05-13 | — | — | US | disclosed |
| US-20210139511-A1 | SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR | INCYTE CORPORATION | 2021-05-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132523-A1 | SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR | CD274, PDCD1, PDCD1LG2 | ALDH1A1 295/4885 |
| US-11866451-B2 | Salts and crystalline forms of a PD-1/PD-L1 inhibitor | CD274, PDCD1, PDCD1LG2 | ALDH1A1 295/4885 |
| US-20210139511-A1 | SALTS AND CRYSTALLINE FORMS OF A PD-1/PD-L1 INHIBITOR | CD274, PDCD1, PDCD1LG2 | ALDH1A1 295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.